 Christopher Lieu
Concepts (366)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 41 | 2023 | 617 | 8.570 |
Why?
| | Molecular Targeted Therapy | 9 | 2019 | 348 | 2.160 |
Why?
| | Antineoplastic Agents | 14 | 2021 | 1893 | 2.140 |
Why?
| | Biomarkers, Tumor | 16 | 2023 | 1048 | 2.080 |
Why?
| | Colonic Neoplasms | 7 | 2023 | 222 | 2.040 |
Why?
| | Rectal Neoplasms | 7 | 2023 | 122 | 1.870 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 16 | 2023 | 1361 | 1.520 |
Why?
| | Neoplasms | 12 | 2022 | 2118 | 1.320 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2019 | 638 | 1.150 |
Why?
| | Immunotherapy | 4 | 2022 | 479 | 1.020 |
Why?
| | Mutation | 12 | 2020 | 3364 | 0.960 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 503 | 0.930 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 4 | 2019 | 228 | 0.880 |
Why?
| | Oncologists | 1 | 2023 | 31 | 0.880 |
Why?
| | Cetuximab | 4 | 2023 | 90 | 0.870 |
Why?
| | Bevacizumab | 4 | 2020 | 118 | 0.870 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2023 | 59 | 0.840 |
Why?
| | Antibodies, Monoclonal | 6 | 2023 | 1265 | 0.810 |
Why?
| | Microsatellite Instability | 6 | 2022 | 32 | 0.760 |
Why?
| | Neuroendocrine Tumors | 5 | 2022 | 83 | 0.750 |
Why?
| | Neoplasm Staging | 11 | 2023 | 1178 | 0.720 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2020 | 667 | 0.720 |
Why?
| | Age of Onset | 7 | 2022 | 450 | 0.690 |
Why?
| | Humans | 82 | 2023 | 115587 | 0.670 |
Why?
| | Piperidines | 2 | 2017 | 163 | 0.640 |
Why?
| | Colectomy | 1 | 2019 | 87 | 0.630 |
Why?
| | Early Detection of Cancer | 2 | 2022 | 340 | 0.620 |
Why?
| | Cyclosporine | 1 | 2018 | 169 | 0.600 |
Why?
| | Terminology as Topic | 1 | 2019 | 186 | 0.590 |
Why?
| | Pancreatic Neoplasms | 6 | 2023 | 722 | 0.590 |
Why?
| | Genetic Predisposition to Disease | 4 | 2022 | 2125 | 0.590 |
Why?
| | Disease-Free Survival | 7 | 2023 | 621 | 0.580 |
Why?
| | Benzimidazoles | 1 | 2018 | 137 | 0.580 |
Why?
| | Azetidines | 1 | 2017 | 31 | 0.580 |
Why?
| | Appendiceal Neoplasms | 2 | 2020 | 14 | 0.560 |
Why?
| | Medical Oncology | 5 | 2023 | 230 | 0.530 |
Why?
| | Healthcare Disparities | 1 | 2021 | 485 | 0.520 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2022 | 81 | 0.510 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2015 | 68 | 0.500 |
Why?
| | Precision Medicine | 1 | 2019 | 344 | 0.500 |
Why?
| | Patient Rights | 1 | 2015 | 10 | 0.500 |
Why?
| | Pyrimidinones | 1 | 2015 | 88 | 0.500 |
Why?
| | Therapies, Investigational | 1 | 2015 | 14 | 0.500 |
Why?
| | Drug and Narcotic Control | 1 | 2015 | 29 | 0.490 |
Why?
| | Drugs, Investigational | 1 | 2015 | 30 | 0.490 |
Why?
| | Pyridones | 1 | 2015 | 125 | 0.480 |
Why?
| | Neovascularization, Pathologic | 2 | 2013 | 283 | 0.480 |
Why?
| | Adenocarcinoma | 5 | 2023 | 799 | 0.470 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 148 | 0.460 |
Why?
| | Pyrazines | 2 | 2018 | 70 | 0.450 |
Why?
| | Middle Aged | 30 | 2022 | 26999 | 0.430 |
Why?
| | Immunoglobulin G | 1 | 2017 | 781 | 0.430 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 166 | 0.430 |
Why?
| | Proto-Oncogene Proteins B-raf | 4 | 2020 | 192 | 0.420 |
Why?
| | Drug Design | 1 | 2013 | 156 | 0.420 |
Why?
| | Neoadjuvant Therapy | 5 | 2023 | 301 | 0.410 |
Why?
| | ErbB Receptors | 5 | 2017 | 557 | 0.410 |
Why?
| | Neoplasm Metastasis | 7 | 2022 | 526 | 0.400 |
Why?
| | Terminal Care | 1 | 2015 | 212 | 0.390 |
Why?
| | Carcinoma, Signet Ring Cell | 1 | 2011 | 3 | 0.390 |
Why?
| | Circulating Tumor DNA | 2 | 2022 | 21 | 0.390 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2013 | 314 | 0.380 |
Why?
| | Aged | 23 | 2022 | 19251 | 0.360 |
Why?
| | Adult | 27 | 2022 | 30718 | 0.360 |
Why?
| | Fibroblast Growth Factors | 1 | 2011 | 162 | 0.360 |
Why?
| | src-Family Kinases | 1 | 2010 | 88 | 0.340 |
Why?
| | Stomach Neoplasms | 3 | 2022 | 66 | 0.330 |
Why?
| | Patient Selection | 3 | 2019 | 654 | 0.330 |
Why?
| | Health Services Accessibility | 1 | 2015 | 771 | 0.320 |
Why?
| | Disease Management | 4 | 2021 | 563 | 0.320 |
Why?
| | Fluorouracil | 4 | 2022 | 151 | 0.320 |
Why?
| | Male | 31 | 2022 | 55949 | 0.310 |
Why?
| | Boronic Acids | 1 | 2008 | 33 | 0.310 |
Why?
| | Janus Kinase 2 | 1 | 2008 | 31 | 0.310 |
Why?
| | Etoposide | 1 | 2008 | 149 | 0.310 |
Why?
| | Carboplatin | 1 | 2008 | 139 | 0.300 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 704 | 0.300 |
Why?
| | Myeloproliferative Disorders | 1 | 2008 | 26 | 0.300 |
Why?
| | Clinical Decision-Making | 3 | 2019 | 273 | 0.300 |
Why?
| | Genomics | 3 | 2022 | 645 | 0.300 |
Why?
| | Female | 31 | 2022 | 59913 | 0.290 |
Why?
| | Kaplan-Meier Estimate | 6 | 2017 | 815 | 0.290 |
Why?
| | Shock, Septic | 1 | 2009 | 185 | 0.290 |
Why?
| | Pathology, Clinical | 2 | 2017 | 32 | 0.280 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2023 | 334 | 0.280 |
Why?
| | Pathology, Molecular | 2 | 2017 | 26 | 0.280 |
Why?
| | Drug Administration Schedule | 4 | 2019 | 724 | 0.270 |
Why?
| | ras Proteins | 2 | 2017 | 138 | 0.260 |
Why?
| | Clinical Trials as Topic | 3 | 2015 | 941 | 0.260 |
Why?
| | Age Factors | 5 | 2021 | 2907 | 0.260 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1357 | 0.250 |
Why?
| | United States | 12 | 2021 | 12295 | 0.230 |
Why?
| | Signal Transduction | 6 | 2018 | 4541 | 0.230 |
Why?
| | Ovarian Neoplasms | 2 | 2020 | 407 | 0.220 |
Why?
| | Metastasectomy | 1 | 2023 | 12 | 0.220 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2022 | 58 | 0.220 |
Why?
| | Trifluridine | 1 | 2022 | 3 | 0.220 |
Why?
| | Disease Models, Animal | 4 | 2021 | 3580 | 0.210 |
Why?
| | Camptothecin | 3 | 2022 | 97 | 0.210 |
Why?
| | Surgical Oncology | 1 | 2022 | 18 | 0.210 |
Why?
| | Genetic Testing | 3 | 2022 | 382 | 0.210 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2022 | 84 | 0.210 |
Why?
| | Survival Rate | 6 | 2023 | 1650 | 0.210 |
Why?
| | Microsatellite Repeats | 1 | 2022 | 137 | 0.210 |
Why?
| | Membrane Proteins | 3 | 2019 | 1024 | 0.200 |
Why?
| | Incidence | 6 | 2022 | 2335 | 0.200 |
Why?
| | Chemoradiotherapy, Adjuvant | 2 | 2023 | 40 | 0.200 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 31 | 0.190 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2022 | 52 | 0.190 |
Why?
| | Health Status Disparities | 2 | 2020 | 204 | 0.190 |
Why?
| | DNA | 1 | 2008 | 1356 | 0.190 |
Why?
| | Pheochromocytoma | 1 | 2022 | 54 | 0.190 |
Why?
| | Meningioma | 1 | 2022 | 78 | 0.190 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 208 | 0.180 |
Why?
| | Capecitabine | 2 | 2022 | 46 | 0.180 |
Why?
| | Practice Patterns, Physicians' | 1 | 2009 | 1180 | 0.180 |
Why?
| | Congresses as Topic | 2 | 2019 | 204 | 0.180 |
Why?
| | Heterografts | 1 | 2021 | 119 | 0.180 |
Why?
| | Treatment Outcome | 10 | 2021 | 9159 | 0.180 |
Why?
| | Consensus | 2 | 2019 | 532 | 0.170 |
Why?
| | Immune System | 1 | 2021 | 173 | 0.170 |
Why?
| | Prognosis | 8 | 2023 | 3339 | 0.170 |
Why?
| | Adenomatous Polyposis Coli Protein | 1 | 2019 | 18 | 0.170 |
Why?
| | Area Under Curve | 2 | 2018 | 278 | 0.170 |
Why?
| | Smad4 Protein | 1 | 2019 | 34 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2022 | 449 | 0.170 |
Why?
| | GTP Phosphohydrolases | 1 | 2019 | 66 | 0.170 |
Why?
| | Disease Progression | 4 | 2017 | 2418 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 1870 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 76 | 0.160 |
Why?
| | Retinal Vein | 1 | 2019 | 13 | 0.160 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2019 | 27 | 0.160 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 139 | 0.160 |
Why?
| | Young Adult | 4 | 2023 | 10470 | 0.160 |
Why?
| | Risk Factors | 6 | 2022 | 8697 | 0.160 |
Why?
| | Cohort Studies | 6 | 2020 | 4944 | 0.160 |
Why?
| | Neoplasm Grading | 1 | 2019 | 244 | 0.160 |
Why?
| | Vasculitis | 1 | 2019 | 71 | 0.160 |
Why?
| | Genes, ras | 1 | 2018 | 91 | 0.150 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1087 | 0.150 |
Why?
| | Drug Combinations | 2 | 2022 | 289 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2019 | 77 | 0.150 |
Why?
| | Survivorship | 1 | 2018 | 38 | 0.150 |
Why?
| | Population Surveillance | 1 | 2021 | 395 | 0.150 |
Why?
| | Risk Assessment | 2 | 2019 | 2987 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 863 | 0.150 |
Why?
| | Neoplasm Transplantation | 1 | 2018 | 235 | 0.150 |
Why?
| | Patient Advocacy | 1 | 2018 | 66 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2019 | 684 | 0.150 |
Why?
| | Esophageal Neoplasms | 1 | 2021 | 273 | 0.150 |
Why?
| | Asthenia | 1 | 2017 | 1 | 0.150 |
Why?
| | Acneiform Eruptions | 1 | 2017 | 1 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 524 | 0.150 |
Why?
| | Drug Eruptions | 1 | 2017 | 26 | 0.150 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6417 | 0.150 |
Why?
| | Hypokalemia | 1 | 2017 | 25 | 0.140 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 199 | 0.140 |
Why?
| | Imidazoles | 1 | 2018 | 217 | 0.140 |
Why?
| | Biomarkers | 3 | 2023 | 3466 | 0.140 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 42 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 193 | 0.140 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2017 | 66 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 154 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2023 | 12608 | 0.140 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2015 | 350 | 0.140 |
Why?
| | Time Factors | 2 | 2019 | 6165 | 0.140 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 157 | 0.140 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 7 | 0.140 |
Why?
| | Cell Line, Tumor | 3 | 2022 | 2751 | 0.140 |
Why?
| | Databases, Factual | 3 | 2017 | 1138 | 0.140 |
Why?
| | Hospitals | 1 | 2021 | 585 | 0.140 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2018 | 281 | 0.130 |
Why?
| | Animals | 9 | 2021 | 32102 | 0.130 |
Why?
| | Edema | 1 | 2016 | 119 | 0.130 |
Why?
| | Diabetic Neuropathies | 1 | 2016 | 79 | 0.130 |
Why?
| | Biliary Tract Neoplasms | 1 | 2015 | 20 | 0.130 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 54 | 0.130 |
Why?
| | Prevalence | 1 | 2022 | 2264 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2016 | 142 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 231 | 0.130 |
Why?
| | Analgesics | 1 | 2016 | 157 | 0.130 |
Why?
| | Device Approval | 1 | 2015 | 21 | 0.130 |
Why?
| | Leucovorin | 3 | 2022 | 42 | 0.120 |
Why?
| | Receptor, Notch1 | 1 | 2015 | 59 | 0.120 |
Why?
| | Neuralgia | 1 | 2016 | 122 | 0.120 |
Why?
| | Pancreas | 1 | 2017 | 280 | 0.120 |
Why?
| | Immunoblotting | 1 | 2015 | 281 | 0.120 |
Why?
| | Health Behavior | 1 | 2020 | 707 | 0.120 |
Why?
| | Deoxycytidine | 1 | 2015 | 140 | 0.120 |
Why?
| | Administration, Oral | 1 | 2017 | 734 | 0.120 |
Why?
| | Gene Dosage | 1 | 2015 | 129 | 0.120 |
Why?
| | Immunoconjugates | 1 | 2016 | 87 | 0.120 |
Why?
| | Phenotype | 2 | 2021 | 2829 | 0.120 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.120 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 156 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2018 | 203 | 0.120 |
Why?
| | Genetic Variation | 1 | 2019 | 877 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 173 | 0.120 |
Why?
| | Quinazolines | 1 | 2015 | 241 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2018 | 521 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2021 | 844 | 0.120 |
Why?
| | Spinal Cord Injuries | 1 | 2016 | 173 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1216 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 1 | 2017 | 609 | 0.110 |
Why?
| | beta Catenin | 1 | 2015 | 220 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 746 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1770 | 0.110 |
Why?
| | Lymphocytes | 1 | 2015 | 344 | 0.110 |
Why?
| | Patient-Centered Care | 1 | 2018 | 477 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 790 | 0.100 |
Why?
| | Prospective Studies | 3 | 2022 | 6264 | 0.100 |
Why?
| | Risk | 1 | 2014 | 819 | 0.100 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 216 | 0.100 |
Why?
| | Patient Care Team | 1 | 2016 | 521 | 0.100 |
Why?
| | Ligands | 1 | 2013 | 569 | 0.100 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 105 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2207 | 0.090 |
Why?
| | Transcriptome | 1 | 2015 | 736 | 0.090 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2013 | 396 | 0.090 |
Why?
| | Apoptosis | 3 | 2022 | 2377 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2013 | 585 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 1853 | 0.080 |
Why?
| | Streptococcaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Neutrophils | 1 | 2015 | 1172 | 0.080 |
Why?
| | Clinical Medicine | 1 | 2009 | 19 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2023 | 187 | 0.080 |
Why?
| | Myositis | 1 | 2009 | 44 | 0.080 |
Why?
| | Bortezomib | 1 | 2008 | 41 | 0.080 |
Why?
| | Mice | 4 | 2021 | 15052 | 0.080 |
Why?
| | Sulindac | 1 | 2008 | 17 | 0.080 |
Why?
| | Taiwan | 1 | 2008 | 15 | 0.080 |
Why?
| | Mutation Rate | 2 | 2019 | 26 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1127 | 0.080 |
Why?
| | Maximum Tolerated Dose | 1 | 2008 | 182 | 0.080 |
Why?
| | Nausea | 1 | 2008 | 103 | 0.080 |
Why?
| | Neutropenia | 1 | 2008 | 127 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 193 | 0.070 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1440 | 0.070 |
Why?
| | Fluphenazine | 1 | 2007 | 5 | 0.070 |
Why?
| | Risperidone | 1 | 2007 | 26 | 0.070 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 41 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 962 | 0.070 |
Why?
| | Exons | 1 | 2008 | 300 | 0.070 |
Why?
| | Anemia | 1 | 2008 | 144 | 0.070 |
Why?
| | Fasting | 1 | 2008 | 241 | 0.070 |
Why?
| | Food | 1 | 2008 | 160 | 0.070 |
Why?
| | Gastrectomy | 2 | 2017 | 83 | 0.070 |
Why?
| | Thrombocytopenia | 1 | 2008 | 175 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2017 | 2161 | 0.070 |
Why?
| | Frontal Lobe | 1 | 2007 | 139 | 0.070 |
Why?
| | Propensity Score | 2 | 2017 | 225 | 0.070 |
Why?
| | Adolescent | 3 | 2020 | 17889 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1000 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 183 | 0.060 |
Why?
| | Survival Analysis | 2 | 2017 | 1219 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2010 | 1093 | 0.060 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2022 | 20 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| | Organoplatinum Compounds | 1 | 2022 | 40 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2022 | 50 | 0.050 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 63 | 0.050 |
Why?
| | Radioisotopes | 1 | 2022 | 34 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2022 | 19 | 0.050 |
Why?
| | Receptors, Peptide | 1 | 2022 | 21 | 0.050 |
Why?
| | Intestinal Neoplasms | 1 | 2022 | 24 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 121 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2022 | 37 | 0.050 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2021 | 29 | 0.050 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 70 | 0.050 |
Why?
| | Europe | 1 | 2022 | 336 | 0.050 |
Why?
| | North America | 1 | 2022 | 261 | 0.050 |
Why?
| | Chimerism | 1 | 2021 | 28 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2022 | 187 | 0.050 |
Why?
| | Canada | 1 | 2022 | 335 | 0.050 |
Why?
| | Preventive Medicine | 1 | 2021 | 39 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2021 | 63 | 0.050 |
Why?
| | Lymphocyte Subsets | 1 | 2021 | 79 | 0.050 |
Why?
| | Hyaluronic Acid | 1 | 2022 | 190 | 0.050 |
Why?
| | Liquid Biopsy | 1 | 2020 | 6 | 0.050 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 284 | 0.050 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2020 | 40 | 0.050 |
Why?
| | Mice, SCID | 1 | 2021 | 321 | 0.040 |
Why?
| | Geography | 1 | 2020 | 181 | 0.040 |
Why?
| | Morbidity | 1 | 2021 | 278 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 195 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 225 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 560 | 0.040 |
Why?
| | Sulfonamides | 1 | 2022 | 447 | 0.040 |
Why?
| | Spectrophotometry, Infrared | 1 | 2019 | 44 | 0.040 |
Why?
| | District of Columbia | 1 | 2018 | 25 | 0.040 |
Why?
| | Karnofsky Performance Status | 1 | 2018 | 36 | 0.040 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 102 | 0.040 |
Why?
| | Colon | 1 | 2020 | 234 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 37 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 511 | 0.040 |
Why?
| | Multimodal Imaging | 1 | 2019 | 98 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 111 | 0.040 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 128 | 0.040 |
Why?
| | Delphi Technique | 1 | 2018 | 164 | 0.040 |
Why?
| | Genome, Human | 1 | 2019 | 352 | 0.040 |
Why?
| | Half-Life | 1 | 2017 | 145 | 0.040 |
Why?
| | Mice, Nude | 1 | 2019 | 639 | 0.040 |
Why?
| | American Medical Association | 1 | 2017 | 17 | 0.040 |
Why?
| | Genomic Instability | 1 | 2017 | 38 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2017 | 182 | 0.030 |
Why?
| | Needles | 1 | 2016 | 52 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 374 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 249 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 123 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2017 | 161 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 431 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 91 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 914 | 0.030 |
Why?
| | Retreatment | 1 | 2016 | 70 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 76 | 0.030 |
Why?
| | Platinum | 1 | 2016 | 40 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3069 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 372 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 445 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 519 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 485 | 0.030 |
Why?
| | Radiography | 2 | 2016 | 826 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 62 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 109 | 0.030 |
Why?
| | Preoperative Care | 1 | 2017 | 318 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1405 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2016 | 339 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2604 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 294 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 684 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1227 | 0.030 |
Why?
| | Ultraviolet Rays | 1 | 2016 | 372 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 203 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 693 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2021 | 980 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 401 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2016 | 472 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4435 | 0.030 |
Why?
| | Skin | 1 | 2016 | 662 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1856 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 4440 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 2262 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1642 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4665 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3672 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 1917 | 0.020 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2009 | 22 | 0.020 |
Why?
| | Rats | 1 | 2016 | 5034 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 60 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 77 | 0.020 |
Why?
| | Reference Standards | 1 | 2008 | 161 | 0.020 |
Why?
| | Quality of Life | 1 | 2018 | 2385 | 0.020 |
Why?
| | Breast Neoplasms | 1 | 2019 | 1872 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 4773 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2008 | 151 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 477 | 0.020 |
Why?
| | Infusions, Intra-Arterial | 1 | 1986 | 45 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2392 | 0.020 |
Why?
| | Hepatic Artery | 1 | 1986 | 52 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1805 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 414 | 0.020 |
Why?
| | Reference Values | 1 | 2007 | 744 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 691 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2007 | 2416 | 0.010 |
Why?
|
|
Lieu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|